Zimmer Biomet Shoulder Arthroplasty PMCF

April 22, 2026 updated by: Zimmer Biomet

Zimmer Biomet Shoulder Arthroplasty Long-term Post Market Clinical Follow-up Study

The objectives of this study are to confirm the safety, performance, and clinical benefits of Zimmer Biomet Shoulder Arthroplasty Systems and its instrumentation in primary or revision shoulder arthroplasty. These objectives will be assessed using standard scoring systems, radiographic evidence, and adverse event records. Safety of the system will be assessed by monitoring the frequency an incidence of adverse events.

Study Overview

Detailed Description

The primary endpoint is defined as survival of the implant at 10 years, which is based on removal or intended removal of at least 1-study implant component and will be determined by using the Kaplan Meier method. The safety of the system will be assessed by monitoring the frequency and incidence of adverse events. Separate analysis will be done for each arm of the study.

The secondary endpoint is represented by the performance and clinical benefits of Zimmer Biomet Shoulder Arthroplasty Systems and its instrumentation after 2 years, which will be assessed by the American Shoulder and Elbow Surgeons (ASES) shoulder score. The secondary endpoint evaluation will also assess the overall pain, functional performance, quality of life and radiographic parameters of all enrolled study subjects.

Study Type

Interventional

Enrollment (Estimated)

584

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Fukui, Japan, 910-3113
        • Active, not recruiting
        • Fukui General Hospital
      • Fukushima, Japan, 973-8555
        • Active, not recruiting
        • Iwaki City Medical Center
      • Okinawa, Japan, 901-0224
        • Active, not recruiting
        • Yuuai Medical Center
      • Tokyo, Japan, 180-0003
        • Withdrawn
        • Kichijoji Minami Hospital
      • Whangarei, New Zealand, 0112
        • Withdrawn
        • Kensington Private Hospital
    • California
      • Irvine, California, United States, 92618
        • Active, not recruiting
        • Hoag Orthopedic Institute
    • Colorado
    • Illinois
      • Chicago, Illinois, United States, 60208
        • Active, not recruiting
        • Northwestern University
    • Kentucky
      • Louisville, Kentucky, United States, 40202
        • Terminated
        • Norton Healthcare, Inc
    • Michigan
      • Royal Oak, Michigan, United States, 48073
        • Active, not recruiting
        • William Beaumont Hospital
    • Minnesota
      • Bloomington, Minnesota, United States, 55431
        • Active, not recruiting
        • TRIA Orthopaedic Center Research Institute
    • Mississippi
      • Jackson, Mississippi, United States, 39202
        • Active, not recruiting
        • Mississippi Sports Medicine and Orthopaedic Center, PLLC
    • Missouri
      • City of Saint Peters, Missouri, United States, 63376
        • Active, not recruiting
        • Advance Bone and Joint
      • St Louis, Missouri, United States, 63130
        • Active, not recruiting
        • Washington University
    • New York
      • Buffalo, New York, United States, 14215
        • Active, not recruiting
        • University of Buffalo
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19107
        • Active, not recruiting
        • Rothman Institute
    • Utah
      • Murray, Utah, United States, 84107
        • Recruiting
        • Intermountain Health
        • Principal Investigator:
          • Aaron Chamberlain, MD
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patient must be 20 years of age or older.
  • Patient must be anatomically and structurally suited to receive shoulder arthroplasty implants.
  • Patient is a candidate for shoulder arthroplasty due to one or more of the following:

    • Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis.
    • Rheumatoid arthritis.
    • Correction of functional deformity.
    • Fractures of the proximal humerus, where other methods of treatment are deemed inadequate.
    • Difficult clinical management problems, where other methods of treatment may not be suitable or may be inadequate.
  • Patient must be able and willing to complete the protocol required follow-up.
  • Patient must be able and willing to sign the IRB/EC approved informed consent.
  • Patient has grossly deficient rotator, (for reverse application)

    • With severe arthropathy and/or
    • Previously failed shoulder joint replacement
  • Patient must have functional deltoid muscle (for reverse application)

Exclusion Criteria:

  • Patient is unwilling or unable to give consent or to comply with the follow-up program.
  • Patient has any condition which would in the judgement of the Investigator, place the patient at undue risk or interfere with the study.
  • Patient is known to be pregnant or breastfeeding.
  • Patient is a vulnerable subject (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, and/or anticipated to be non-compliant).
  • Patient is uncooperative or patient with neurologic disorders who is incapable or unwilling to follow directions.
  • Patient has any sign of infection affecting the shoulder joint or in its proximity which may spread to the implant site.
  • Patient has rapid joint destruction, marked bone loss, or bone resorption apparent on roentgenogram.
  • Patient has any neuromuscular disease compromising the affected limb that would render the procedure unjustifiable.
  • Patient presents with osteoporosis, which in the opinion of the Investigator, may limit the subject's ability to support total shoulder arthroplasty using the study device.
  • Patient has osteomalacia.
  • Patient has a metabolic disorder that may impair bone formation.
  • Patient has deficient rotator cuff.
  • Patient presents with significant injury to the upper brachial plexus.
  • Patient has paralysis of the axillary nerve.
  • Patient has non-functional deltoid or external rotator muscles.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Zimmer Biomet Total Shoulder Arthroplasty System
Patients who are having primary or revision total shoulder arthroplasty who will receive a Zimmer Biomet Total Shoulder Arthroplasty System.
Alliance Glenoid used in Primary or Revision Total Shoulder Arthroplasty
Other Names:
  • Alliance
Identity Shoulder System is intended to be used in anatomic total shoulder arthroplasty, shoulder hemi-arthroplasty, or total reverse shoulder arthroplasty in both Primary or Revision Total Shoulder Arthroplasty
Other Names:
  • Identity

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Implant Survivorship at 10 years follow-up (Kaplan Meier)
Time Frame: 10 years
Based on removal or intended removal of the device and determined using the Kaplan-Meier method.
10 years
Frequency and Incidence of Adverse Events (Safety)
Time Frame: 10 years
Monitoring the frequency and incidence of adverse events, serious adverse events, adverse device effects, serious adverse device effects, and unanticipated serious adverse device effects as well as device deficiencies.
10 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical efficacy of the device is assessed using the American Shoulder and Elbow Surgeons (ASES) Shoulder Score at 2 years follow-up
Time Frame: 2 years
Pain, function, and activities of daily living are measured. The ASES scale is 0-100. 100 is the highest score and indicates the greatest function while 0 is the lowest score.
2 years
Euroqol Patient Quality of life measured at 2 years follow-up (EQ-5D-5L)
Time Frame: 2 years
The EuroQol five dimensions questionnaire (EQ-5D-5L) is a five dimensional self-assessment that is comprised of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. These five dimensions can be used to index a subject's health utility on a scale of 0 to 1, where 0 is death and 1 is perfect health. The scoring rule for EQ-5D permits scores less than 0, implying that some health states may be worse than death.
2 years
Radiographic Performance [Radiolucency] at 2 years follow-up
Time Frame: 2 years
X-rays will be evaluated for radiolucency lines to show the number of subjects with radiolucency. Radiolucency refers to structures that are less dense and permit the x-ray beam to pass through them. Radiolucent structures appear dark or black in the radiographic image.
2 years
Radiographic Performance [Osteolysis] at 2 years follow-up
Time Frame: 2 years
X-rays will be evaluated for osteolysis to show the number of subjects with osteolysis. Osteolysis is a progressive condition where bone tissue is destroyed. In this process, bones lose minerals (mostly calcium), softens, degenerates and become weaker.
2 years
Radiographic Performance [Heterotopic Ossification] at 2 years follow-up
Time Frame: 2 years
X-rays will be evaluated for heterotopic ossification to show the number of subjects with heterotopic ossification. Heterotopic ossification refers to the presence of bone in soft tissue where bone normally does not exist (extraskeletal bone).
2 years
Radiographic Performance [Humeral Component Subsidence] at 2 years follow-up
Time Frame: 2 year
X-rays will be evaluated for humeral component subsidence to show the number of subjects with subsidence. Component Subsidence refers to the presence of the device component gradually sinking or caving into the bone structure.
2 year
Radiographic Performance [Glenoid Component Migration] at 2 years follow-up
Time Frame: 2 year
X-rays will be evaluated for glenoid component migration to show the number of subjects with migration. Component migration refers to the presence of the device component gradually moving anteriorly, posteriorly, superiorly, or inferiorly in relation to original placement.
2 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Ryan Boylan, Zimmer Biomet

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 28, 2021

Primary Completion (Estimated)

August 15, 2033

Study Completion (Estimated)

August 15, 2033

Study Registration Dates

First Submitted

July 16, 2021

First Submitted That Met QC Criteria

July 29, 2021

First Posted (Actual)

July 30, 2021

Study Record Updates

Last Update Posted (Actual)

April 28, 2026

Last Update Submitted That Met QC Criteria

April 22, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe